Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2.
Tomislav
T
Smoljanovic
Franjo
F
Siric
Ivan
I
Bojanic
D001174:Arthrodesis / Q000009:adverse effects* / Q000295:instrumentation / Q000379:methods*; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D004542:Ejaculation; D005781:Gelatin Sponge, Absorbable; D005832:Genital Diseases, Male / Q000209:etiology*; D006801:Humans; D008159:Lumbar Vertebrae / Q000601:surgery*; D008297:Male; D011183:Postoperative Complications / Q000209:etiology*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013168:Spondylolisthesis / Q000601:surgery; D016212:Transforming Growth Factor beta / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta